Codi QR

Neoadjuvant checkpoint inhibitor immunotherapy for resectable mucosal melanoma

BackgroundNeoadjuvant checkpoint inhibition (CPI) has recently demonstrated impressive outcomes in patients with stage 3 cutaneous melanoma. However, the safety, efficacy, and outcome of neoadjuvant CPI in patients with mucosal melanoma (MM) are not well studied as MM is a rare melanoma subtype. CPI...

Descripció completa

Guardat en:
Autors principals: Joel Ho, Jane Mattei, Michael Tetzlaff, Michelle D. Williams, Michael A. Davies, Adi Diab, Isabella C. Glitza Oliva, Jennifer McQuade, Sapna P. Patel, Hussein Tawbi, Michael K. Wong, Sarah B. Fisher, Ehab Hanna, Emily Z. Keung, Merrick Ross, Roi Weiser, Shirley Y. Su, Michael Frumovitz, Larissa A. Meyer, Amir Jazaeri, Curtis A. Pettaway, B. Ashleigh Guadagnolo, Andrew J. Bishop, Devarati Mitra, Ahsan Farooqi, Roland Bassett, Silvana Faria, Priyadharsini Nagarajan, Rodabe N. Amaria
Format: Artigo
Idioma:Inglês
Publicat: Frontiers Media S.A. 2022-10-01
Col·lecció:Frontiers in Oncology
Matèries:
mucosal melanoma
immunotherapy
melanoma
neoadjuvant
resectable
Accés en línia:https://www.frontiersin.org/articles/10.3389/fonc.2022.1001150/full
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars